Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Asuragen introduces new Quantidex Pan Cancer kit

Molecular diagnostics firm Asuragen has introduced new Quantidex Pan Cancer Kit, a workflow solution for targeted next-generation sequencing (NGS).

The NGS oncology panel is said to provide a comprehensive workflow solution, which incorporates reagents, controls and a novel bioinformatics suite for the sequencing of 21 genes relevant to a diverse set of human cancers.

Quantidex Pan Cancer Kit has been developed to examine difficult sample types such as formalin-fixed paraffin embedded (FFPE) and fine-needle aspiration (FNA) tissues.

Integrating a modular workflow design that can facilitate content expansion, the kit allows to assimilate both DNA and RNA targets and provides a complete targeted NGS solution for laboratories wishing to adopt NGS.

The kit offers streamlined wet-bench protocol and companion push-button analysis software that enables rapid training and implementation even for laboratories with little to no NGS experience or informatics infrastructure.

The product includes pre-analytical DNA QC, sample quantification, multiplex PCR enrichment, dual-index barcoding, and library purification and quantification using reagents in a single kit.

In addition, the product comprises firm’s Quantidex DNA Assay for sample quantification and qualification. It helps to improve variant calling in tumor samples by relaying sample DNA copy number information to the bioinformatics software for analysis using a patent-pending method.

The kit integrates both synthetic multi-variant process control and an authentic FFPE control, which enhances the confidence of mutation calling in each run.